Simple Urine Cortisol Test May Pinpoint Dangerous Cushing's Subtype
A Spanish multicenter study finds urinary cortisol thresholds can reliably distinguish two life-threatening forms of Cushing's syndrome.
Summary
Cushing's syndrome caused by excess ACTH comes in two forms: Cushing's disease (a pituitary tumor) and ectopic ACTH secretion (EAS), often from a hidden cancer. Telling them apart is notoriously difficult and delays life-saving treatment. This Spanish study of 269 patients found that measuring urinary free cortisol as a multiple of the upper limit of normal (UFC×ULN) is a powerful, noninvasive way to separate the two. No EAS case occurred below 3×ULN, while 40% of patients above 10×ULN had EAS. Adding late-night salivary cortisol and low potassium (hypokalemia) to the equation identified 75% of EAS cases with 98% specificity. These findings support a practical triage approach: high cortisol plus low potassium should trigger urgent whole-body imaging to hunt for a hidden tumor.
Detailed Summary
Distinguishing ectopic ACTH secretion (EAS) from Cushing's disease (CD) is one of endocrinology's hardest diagnostic challenges. EAS is frequently caused by occult malignancies — small-cell lung cancer, carcinoid tumors — and delays in diagnosis worsen outcomes. Current gold-standard tests like inferior petrosal sinus sampling are invasive, expensive, and not universally available. A simpler biochemical triage tool is urgently needed.
Researchers from the Spanish Cushing Registry conducted a multicenter retrospective study of 269 patients with confirmed ACTH-dependent Cushing's syndrome — 208 with CD and 61 with EAS — managed at tertiary referral centers. They evaluated whether urinary free cortisol expressed as multiples of the upper limit of normal (UFC×ULN) could reliably discriminate between the two subtypes, and whether adding late-night salivary cortisol (LNSC×ULN) and hypokalemia improved accuracy.
The results were striking. EAS patients were older (median 59 vs. 45 years) and showed dramatically higher UFC×ULN (16.6 vs. 3.6) and LNSC×ULN (9.3 vs. 1.5). Both markers achieved excellent discriminative performance, with AUCs of 0.90 and 0.92 respectively. Crucially, no EAS case was found below UFC 3×ULN, providing a practical lower-bound safety threshold. At the upper end, 40.5% of patients with UFC ≥ 10×ULN had EAS. Combining severe hypercortisolism (UFC ≥ 10×ULN and LNSC ≥ 9×ULN) with hypokalemia identified 75% of EAS cases at 98% specificity.
For clinicians, these findings support a pragmatic two-track approach: patients with mild hypercortisolism can proceed directly to pituitary-focused MRI and dynamic testing, while those with severe cortisol elevation plus hypokalemia should undergo urgent whole-body imaging to locate an occult tumor. This could meaningfully shorten the diagnostic odyssey for EAS patients.
Limitations include the retrospective design, potential referral bias at tertiary centers, and the fact that this summary is based on the abstract only. External validation in non-Spanish populations is still needed before universal adoption.
Key Findings
- No EAS case occurred with UFC below 3× the upper limit of normal — a reliable lower-bound threshold.
- 40.5% of patients with UFC ≥ 10×ULN had ectopic ACTH secretion, not Cushing's disease.
- Late-night salivary cortisol achieved AUC 0.92 for distinguishing EAS from CD.
- Severe hypercortisolism plus hypokalemia identified 75% of EAS cases with 98% specificity.
- EAS patients were significantly older (median 59 vs. 45 years), adding age as a clinical clue.
Methodology
Multicenter retrospective study using the Spanish Cushing Registry, including 269 patients (208 CD, 61 EAS) from tertiary referral centers. Diagnostic accuracy was assessed via ROC curve analysis, with AUC, sensitivity, specificity, and predictive values reported. UFC and LNSC were expressed as multiples of each lab's upper limit of normal to allow cross-center comparison.
Study Limitations
The retrospective design and recruitment from tertiary centers introduce potential selection and referral bias, limiting generalizability to community settings. The study population is exclusively Spanish, and external validation in diverse populations is needed. This summary is based on the abstract only, as the full text was not available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.